skip to main content
Idioma:

The influence of methylphenidate on sustained attention in paediatric acquired brain injury: a meta-analytical review

Hagan, Alexander J. ; Verity, Sarah J.

Child neuropsychology, 2023-07, Vol.29 (5), p.710-741 [Periódico revisado por pares]

England: Routledge

Texto completo disponível

Citações Citado por
  • Título:
    The influence of methylphenidate on sustained attention in paediatric acquired brain injury: a meta-analytical review
  • Autor: Hagan, Alexander J. ; Verity, Sarah J.
  • Assuntos: Attention ; Attention Deficit Disorder with Hyperactivity - drug therapy ; Brain Injuries ; brain injury ; brain tumor ; Central Nervous System Stimulants - pharmacology ; Central Nervous System Stimulants - therapeutic use ; Child ; cognition ; Humans ; methylphenidate ; Methylphenidate - pharmacology ; Methylphenidate - therapeutic use ; pediatric
  • É parte de: Child neuropsychology, 2023-07, Vol.29 (5), p.710-741
  • Notas: SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    ObjectType-Review-1
    ObjectType-Article-3
  • Descrição: Impairment in sustained attention is a common consequence of childhood Acquired Brain Injury (ABI). Whilst methylphenidate provides promise in enhancing "attention" as a unitary construct, little work has explored its effectiveness upon individual attentional domains. The current systematic review and meta-analysis evaluates the utility of methylphenidate on sustained attentional performance across childhood ABI groups. Five databases (PsycINFO, MEDLINE, Embase, Scopus & Cochrane Library) were searched for relevant articles from their inception to March 2022. A purpose-developed evaluation tool was used to assess each study's research quality (QuEST:MAP). Nine of the 1600 identified articles were included within this review (n = 259). Meta-analytical findings reported an overall significant benefit of methylphenidate on sustained attention in childhood ABI (g = −0.33, 95% CI: −0.62 to −0.04). Associated summary effect sizes were relatively small, particularly when adjusting for outlier cases. Subgroup analyses identified a significantly greater benefit of methylphenidate in clinical subgroups with comorbid ADHD diagnoses (p < .01). The current evidence base is characterized by small-scale clinical trials with variable research quality and low generalizability. Further robust research is needed to quantify methylphenidate utility upon individual attentional domains in larger and more representative ABI samples.
  • Editor: England: Routledge
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.